104014-22-4

Basic information

• Product Name: Benzoic acid, 2,2'-(methylimino)bis-, dimethyl ester
• CAS NO: 104014-22-4
• Molecular Formula: C17H17NO4
• Molecular Weight: 299.326
• Mol File: 104014-22-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2,2'-(methylimino)bis-, dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2,2'-(methylimino)bis-, dimethyl ester(104014-22-4)
• EPA Substance Registry System: Benzoic acid, 2,2'-(methylimino)bis-, dimethyl ester(104014-22-4)

Safety Data

• Hazardous Substances Data: 104014-22-4(Hazardous Substances Data)

Upstream product

• 610-97-9 o-iodo-methyl-benzoic acid 
• 85-91-6 Methyl N-methylanthranilate 
• 124-38-9 carbon dioxide 
• 10072-05-6 methyl 2-(dimethylamino)benzoate 
• 88284-48-4 2-(trimethylsilyl)phenyl trifluoromethanesulfonate 
• 34069-89-1 methyl 2‐[2‐(methoxycarbonyl)phenylamino]benzoate 
• 74-88-4 methyl iodide 

Downstream Products

• 104257-39-8 2,2'-(methylazanediyl)dibenzoic acid 

Relevant articles and documents

Substrate-Controlled Selectivity Switch in the Three-Component Coupling Involving Arynes, Aromatic Tertiary Amines, and CO2

The transition-metal-free multicomponent coupling involving arynes, aromatic tertiary amines, and CO2 is reported. The reaction exhibits switchable selectivity depending on the electronic nature of the aromatic amines used. With amines bearing electron-releasing/neutral groups as the nucleophilic trigger, the reaction afforded 2-arylamino benzoates via a nitrogen to oxygen alkyl group migration. Employing electron-deficient amines in the reaction furnished 2-aminoaryl benzoates proceeding via the aryl to aryl amino group migration resembling a Smiles rearrangement.

BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS

This invention is directed to compounds of formula (I): wherein m, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.